The pharma ADMET testing market is estimated at $7.43bn in 2016 and is expected to grow at a CAGR of 12.32% in the first half of the forecast period. The market is expected to grow at a CAGR of 10.50% in the second half of the forecast period. In 2016, the largest sector of the market was in vitro testing, which accounted for 44.3% of the ADMET testing market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 149-page report you will receive 100 charts– all unavailable elsewhere.
The 149-page report provides clear detailed insight into the pharma ADMET testing market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Pharma ADMET Testing market forecasts from 2017-2027
• This report also breaks down the revenue forecast for the main submarkets:
– In Vivo ADMET Testing
– In Vitro ADMET Testing
– In Silico ADMET Testing
• This report provides individual revenue forecasts to 2027 for these regional and national markets:
– The US
– Japan
– Germany
– France
– Italy
– Spain
– The UK
– China
– Brazil
– Russia
– India
– South Korea
– Rest of the World
• Our study includes SWOT and STEP analysis of this industry and market.
• Our study discusses the selected leading companies that are the major players in the ADMET Testing industry:
– Agilent Technologies
– BIOVIA
– Cyprotex
– Bio-Rad Laboratories
– Quintiles
– CMIC
– Charles River Laboratories
– WuXi PharmaTech
– Promega Corporation
– Sigma-Aldrich (part of Merck KGaA)
A company profile gives you the following information where available:
• Recent historical revenues
• Discussion of a company’s activities, technologies and outlook
• Brief assessment of the company’s ADMET strategy
Visiongain’s study is intended for anyone requiring commercial analyses for the pharma ADMET Testing market. You find data, trends and predictions.
Buy our report today Pharma ADMET Testing Market 2017-2027: In Vitro, In Vivo, In Silico, Leading Developed Markets, Leading Emerging Markets, Leading Companies.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Overview of the World Market for ADMET Testing
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. An Introduction to ADMET Testing
2.1 What Is ADMET Testing?
2.1.1 Absorption
2.1.2 Distribution
2.1.3 Metabolism
2.1.3.1 MIST Guidelines
2.1.4 Excretion
2.1.5 Toxicology
2.2 The Role of ADMET Testing in Biosimilarity
2.3 Trial Design and Execution
2.3.1 Phases of Drug Development
2.3.1.1 Phase 0 Trials: Establishing Pharmacodynamic and Pharmacokinetic Properties
2.3.1.2 Phase I Trials: First-In-Human Studies
2.3.1.3 Phase II Trials: Proof-Of-Concept
2.3.1.4 Phase III Trials: Preparing for Approval Applications
2.3.1.5 Post-Marketing Studies
2.3.2 Reducing Attrition Rates in Drug Development through Predictive ADMET
2.3.3 Benefits of Outsourcing
3. ADMET Testing: World Market 2015-2027
3.1 Pharma R&D Expenditures by Phase, 2014
3.1.1 The Impact of the Economy on the ADMET Testing Market, 2008-2014
3.1.2 Big Pharma Companies Are the Leading Clients for CROs
3.2 The ADMET Testing Market 2015-2027
3.2.1 What Will Drive Growth in ADMET Testing 2015-2027?
3.2.2 The ADMET Testing Market: Overall Revenue Forecast 2015-2027
4. ADMET Testing: Revenue by Segment 2015-2027
4.1 Which Market Sector Will Account for the Most Revenue from 2015-2027?
4.2 Rising Demand for Predictive ADMET Testing Throughout the Decade
4.3 In Vitro ADMET Testing Market
4.3.1 In Vitro ADMET Testing: Drivers and Restraints
4.4 In Vivo ADMET Testing Market
4.4.1 In Vivo ADMET Testing: Drivers and Restraints
4.5 In Silico ADMET Testing
4.5.1 In Silico ADMET Testing: Drivers and Restraints
5. ADMET Testing: Leading Developed Markets 2015-2027
5.1 Leading National Markets for ADMET Testing 2016
5.2 ADMET Testing: Leading National Market Forecasts 2015-2027
5.3 North America as a Destination for Drug Development
5.3.1 The US: The Largest National Market for ADMET Testing 2015-2027
5.3.1.1 Government Programs to Improve ADMET in the US
5.3.2 The US: ADMET Testing Revenue Forecast 2015-2027
5.4 The Outlook for ADMET Testing in the EU5 2015-2027
5.4.1 Rewriting the Rules for Clinical Trials in the EU: Clinical Trials Regulation
5.4.2 EU5: Overall Market and Leading National Market Forecasts 2015-2027
5.4.3 Germany: Market Forecast 2015-2027
5.4.4 The UK
5.4.4.1 Overcoming Challenges in UK Clinical Trials
5.4.4.2 UK ADMET Testing Market Forecast 2015-2027
5.4.5 France: Market Forecast 2015-2027
5.4.6 Italy: Market Forecast 2015-2027
5.4.7 Spain: Market Forecast 2015-2027
5.5 Japan Is Being Challenged by Neighbouring Emerging Markets
5.5.1 Growth for ADMET Testing in Japan 2015-2027
6. ADMET: Leading Emerging Markets 2015-2027
6.1 Leading Emerging Markets for ADMET Testing 2016
6.1.1 Benefits of Conducting ADMET Testing in Emerging Markets
6.1.2 Challenges of Conducting Non-Clinical Studies in Emerging Markets
6.2 Strong Growth Forecast for Emerging ADMET Testing Markets 2015-2027
6.3 ADMET in Asia Pacific: An Emerging Market Perspective
6.3.1 China Will be the Largest Emerging Market for ADMET Testing in 2025
6.3.1.1 CRO Investments and Partnerships in China
6.3.1.2 Chinese ADMET Testing Market Forecast 2015-2027
6.3.2 India as a Hub for Clinical Trials
6.3.2.1 Indian ADMET Testing Market Forecast 2015-2027
6.3.3 South Korea
6.3.3.1 Promoting Local Drug Development in South Korea
6.3.3.2 Growth in the South Korean ADMET Market 2015-2027
6.4 Russia
6.4.1 Changing Drug Development Demands 2010-2015
6.4.2 Russian ADMET Market Forecast 2015-2027
6.5 Brazil: The Largest Market for Drug Development in Latin America 2015-2027
6.5.1 Brazilian ADMET Testing Market Forecast 2015-2027
7. Leading Companies in the ADMET Testing Industry
7.1 Agilent Technologies, Inc.
7.1.1 Agilent Technologies, Inc.: Historical Revenues 2014-2016
7.1.2 Agilent Technologies, Inc. Acquires Cartagenia
7.2 Dassault Systèmes: Acquires Accelrys and forms BIOVIA
7.2.1 Accelrys: Historical Revenues 2011-2013
7.3 Cyprotex
7.3.1 Evotec AG acquires Cyprotex
7.3.2 Cyprotex Acquires CeeTox
7.3.3 Cyprotex Historical Revenues, 2010-2014
7.4 Bio-Rad Laboratories, Inc.
7.4.1 Bio-Rad Laboratories, Inc.: Historical Revenues 2014-2016
7.5 Quintiles
7.5.1 Merger with IMS Health
7.5.2 Expanding in Developed and Emerging Markets
7.6 Increasing Asian Regional Reach
7.6.1 CMIC Recent and Future Performance Analysis: An Asian Specialist
7.7 Charles River Laboratories Is an Expert in Pre-Clinical Services
7.8 WuXi PharmaTech
7.8.1 Merger with New WuXi Life Science Limited and WuXi Merger Limited
7.8.2 WuXi Acquires XenoBiotic Laboratories
7.8.3 WuXi Enters the Clinical Trial Services Market
7.9 Promega Corporation
7.10 Merck KGaA’s Acquisition of Sigma Aldrich
8. ADMET Testing Market: Industry Trends 2015-2027
8.1 Strengths and Weaknesses of the ADMET Testing Market
8.2 Opportunities and Threats in the ADMET Testing Market
8.3 ADMET Testing Market: STEP Analysis 2015-2027
8.3.1 Social Factors Affecting ADMET 2015-2027
8.3.2 Drug Developers Must Deal with Ethical Concerns for Animal Testing
8.4 Improving Technology for More Efficient Testing: High-Throughput Evaluation and In Vivo-Like Models
8.5 Economic Considerations for ADMET Testing 2015-2027
8.5.1 Demand for Predictive ADMET Testing
8.6 Political and Regulatory Developments Affecting ADMET Testing 2015-2027
8.6.1 Cutting Red Tape and Other Regulatory Developments in Drug Discovery and Development
8.6.2 Strategic Partnering for Long Term Revenue Growth
8.6.2.1 Sharing Risk Between Pharma and CROs
8.6.3 A Note on CRO Selection
8.6.3.1 Small Pharmaceutical Companies and CROs
8.6.4 CRO Consolidation is Decreasing the Number of Mid-Sized Market Players
9. Conclusions from Our Study
9.1 The World ADMET Testing Market in 2016
9.1.1 A Market Dominated by the Developed Countries
9.2 Strong Growth for the Overall Market 2015-2027
9.3 Which CROs Can Take Best Advantage of Market Growth in the Next 10 Years?
9.3.1 How Can CROs Specialise to Remain Competitive?
Appendices
Visiongain’s Bespoke Research Service
Some Associated Reports
Report Sales Order Form
About Visiongain
Report Evaluation Form
List of Tables
Table 1.1 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2015 and 2016
Table 2.1 Pharmacokinetics: Description of ADME
Table 2.2 Drug Delivery Routes
Table 2.3 Biosimilar Guidance Drafted Using Elements of EU Guidelines, 2008-2015
Table 2.4 Founding Members of the ICH
Table 3.1 Breakdown of R&D Expenditures by Phase, 2014
Table 3.2 CRO Services Revenue by Customer Type, 2014
Table 3.3 ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 4.1 ADMET Testing Submarket Revenue ($bn) and Market Shares (%), 2017, 2020, and 2027
Table 4.2 ADMET Testing Submarket Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 4.3 In Vitro ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 4.4 In Vivo ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 4.5 In Silico ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.1 World ADMET Testing Market by National Market: Revenue ($bn) and Market Share (%), 2016
Table 5.2 ADMET Testing Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.3 ADMET Testing: Market Shares by Country, 2016, 2020 and 2027
Table 5.4 US ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.5 EU5 ADMET Testing Market by Country, 2016
Table 5.6 EU5 ADMET Testing Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.7 German ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.8 UK ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.9 French ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.10 Italian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.11 Spanish ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.12 Japanese ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 6.1 Leading Emerging Markets for ADMET Testing, 2016
Table 6.2 Population Statistics in BRIC Nations, 2016
Table 6.3 English Proficiency in Emerging Markets, 2014
Table 6.4 ADMET Testing Market Forecast in Emerging Markets: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 6.5 Chinese ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 6.6 Indian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 6.7 South Korean ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 6.8 Russian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 6.9 Brazilian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 7.1 Selected Companies in the ADMET Testing Industry, 2016
Table 7.2 Selected Agilent Technologies MS Products, 2016
Table 7.3 Agilent Technologies: Revenue ($bn), AGR (%) and CAGR (%), 2014-2016
Table 7.4 Agilent Technologies: Revenue ($bn) and Revenue Share (%) by Sector, 2015 and 2016
Table 7.5 Accelrys: Revenue ($bn), AGR (%) and CAGR (%), 2011-2013
Table 7.6 Cyprotex ADME & PK Services, 2016
Table 7.7 Cyprotex In Vitro Toxicology Services, 2016
Table 7.8 Cyprotex In Silico Services, 2016
Table 7.9 Cyprotex: Revenue ($bn and £bn), AGR (%) and CAGR (%), 2011-2014
Table 7.10 Bio-Rad Laboratories: Revenue ($bn), AGR (%) and CAGR (%), 2014-2016
Table 7.11 Quintiles: Service Revenue ($bn), AGR (%) and CAGR (%), 2014-2016
Table 7.12 CMIC: CRO Service Revenue ($bn and ¥bn), AGR (%) and CAGR (%), 2014-2016
Table 7.13 Charles River Laboratories: Revenue ($bn) and Revenue Share (%) by Sector, 2015 and 2016
Table 7.14 WuXi PharmaTech: Revenue ($bn) and CAGR (%) by Sector, 2012-2014
Table 8.1 ADMET Testing Market: Strengths and Weaknesses, 2016
Table 8.2 ADMET Testing Market: Opportunities and Threats, 2016
Table 8.3 ADMET Testing Market: STEP Analysis, 2016
Table 9.1 ADMET Testing Market by Sector: Revenue ($bn) and CAGR (%), 2016, 2020 & 2027
List of Figures
Figure 2.1 Drug Design Process
Figure 2.2 ADMET Parameters
Figure 3.1 Breakdown of Pharma Clinical Spending by Phase, 2014
Figure 3.2 CRO Services Revenue by Customer Type, 2014
Figure 3.3 ADMET Testing Market: Drivers and Restraints, 2015-2027
Figure 3.4 ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
Figure 4.1 ADMET Testing Market Revenue ($bn) by Submarket, 2017, 2020 and 2027
Figure 4.2 ADMET Testing Submarket Shares (%), 2017
Figure 4.3 ADMET Testing Submarket Shares (%), 2020
Figure 4.4 ADMET Testing Submarket Shares (%), 2027
Figure 4.5 ADMET Testing Market Revenue ($bn) Forecast by Submarket, 2015-2027
Figure 4.6 In Vitro ADMET Revenue ($bn) Forecast, 2015-2027
Figure 4.7 In Vitro ADMET: Drivers and Restraints, 2015-2027
Figure 4.8 In Vivo Submarket Revenue ($bn) Forecast, 2015-2027
Figure 4.9 In Vivo ADMET: Drivers and Restraints, 2015-2027
Figure 4.10 In Silico Testing Submarket Revenue ($bn) Forecast, 2015-2027
Figure 4.11 In Silico Submarket: Drivers and Restraints, 2015-2027
Figure 5.1 World ADMET Testing Market by National Market: Market Share (%), 2016
Figure 5.2 World ADMET Testing Market by National Market: Market Share (%), 2020
Figure 5.3 World ADMET Testing Market by National Market: Market Share (%), 2027
Figure 5.4 US ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
Figure 5.5 EU5 ADMET Testing Market Share (%) by Country, 2016
Figure 5.6 EU5 ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
Figure 5.7 German ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
Figure 5.8 UK ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
Figure 5.9 French ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
Figure 5.10 Italian ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
Figure 5.11 Spanish ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
Figure 5.12 Japanese ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
Figure 6.1 Leading Emerging Markets for ADMET Testing by Market Share (%), 2016
Figure 6.2 Cost Savings Available for Clinical Trials in Emerging Markets, 2014
Figure 6.3 Relative Competence in English in Emerging Markets, 2014
Figure 6.4 ADMET Testing: Emerging Market Revenue ($bn) Forecasts, 2015-2027
Figure 6.5 Chinese ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
Figure 6.6 Indian ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
Figure 6.7 South Korean ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
Figure 6.8 Russian ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
Figure 6.9 Brazilian ADMET Testing Market Revenue ($bn) Forecast, 2015-2027
Figure 7.1 Agilent Technologies: Revenue ($bn) and AGR (%), 2014-2016
Figure 7.2 Agilent Technologies: Revenue Share (%) by Sector, 2016
Figure 7.3 Accelrys: Revenue ($bn) and AGR (%), 2011-2013
Figure 7.4 Cyprotex: Revenue ($bn) and AGR (%), 2011-2014
Figure 7.5 Bio-Rad Laboratories: Revenue ($bn) and AGR (%), 2014-2016
Figure 7.6 Quintiles: Service Revenue ($bn) and AGR (%), 2014-2016
Figure 7.7 CMIC: CRO Service Revenue ($bn) and AGR(%), 2014-2016
Figure 7.8 Charles River Laboratories Clinical Trials: Revenue ($bn) by Sector, 2015 and 2016
Figure 7.9 WuXi PharmaTech: Revenue ($bn) by Sector, 2012-2014
Figure 9.1 ADMET Testing Market Revenue ($bn) by Sector, 2016, 2020 & 2027
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
